Evidence map›Paper›PMID 40255182›Full record

Trial reportCirculation2025

Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.

Andre Zimerman, Ana Laura F Kunzler, Brittany N Weber, Xinhui Ran, Sabina A Murphy, Huei Wang, Narimon Honarpour, Anthony C Keech, Peter S Sever, Marc S Sabatine and 1 more

2 registry-linked trialsAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01764633. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01764633 phase3completed

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease

Ran2013Enrolled27,564Registered outcomes9Posted comparisons9ConditionsDyslipidemiaArmsEvolocumab, Placebo
PMID 28304224PMID 31166576PMID 37344040PMID 35760720PMID 28832867other papers from this trial
Open the trial in the graph
NCT07373847 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Single-center, Randomized, Placebo-controlled Trial Study to Compare Efficacy, Safety and Tolerability of Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia

TypeinterventionalSponsorXiangya Hospital of Central South UniversityRan2026 to 2027Enrolled40ConditionsPlaque PsoriasisArmsvunakizumab and recaticimab., vunakizumab and placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andre ZimermanHospital Moinhos de Vento, Moinhos de Vento College of Health Sciences, Porto Alegre, Brazil (A.Z., A.L.F.K.).ORCID 0000-0001-8977-6929
Ana Laura F KunzlerHospital Moinhos de Vento, Moinhos de Vento College of Health Sciences, Porto Alegre, Brazil (A.Z., A.L.F.K.).ORCID 0009-0004-0976-5779
Brittany N WeberDivision of Cardiovascular Medicine (B.N.W.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-0177-2091
Xinhui RanTIMI Study Group (X.R., S.A.M., M.S.S., R.P.G.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-4299-5299
Sabina A MurphyTIMI Study Group (X.R., S.A.M., M.S.S., R.P.G.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-8231-3611
Huei WangBiostatistics (H.W.), Amgen, Thousand Oaks, CA.
Narimon HonarpourGlobal Development (N.H.), Amgen, Thousand Oaks, CA.
Anthony C KeechSydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia (A.C.K.).ORCID 0000-0002-9426-9136
Peter S SeverNational Heart and Lung Institute, Imperial College London, UK (P.S.S.).ORCID 0000-0003-0421-2409
Marc S SabatineTIMI Study Group (X.R., S.A.M., M.S.S., R.P.G.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-0691-3359
Robert P GiuglianoTIMI Study Group (X.R., S.A.M., M.S.S., R.P.G.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-4110-7675

Funding

Advanced CV imaging and immunophenotyping to study coronary vascular health in psoriasisK23HL159276 · UT SOUTHWESTERN MEDICAL CENTER · 2025 to 2025
$194k
NHLBI NIH HHS K23 HL159276
6 · The paper itself

Abstract

backgroundPatients with an autoimmune or inflammatory disease (AIID) are at increased cardiovascular risk and may benefit more from statin therapy. In the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab lowered low-density lipoprotein cholesterol levels, but not hsCRP (high-sensitivity C-reactive protein) levels, and reduced the risk of cardiovascular events.

methodsFOURIER was a randomized trial of evolocumab versus placebo in 27 564 patients with stable atherosclerosis who were taking statins. This analysis focused on the effect of evolocumab in patients with or without an AIID, defined as any autoimmune or chronic inflammatory condition. The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, unstable angina, or coronary revascularization.

resultsAt baseline, 889 patients (3.2%) had an AIID, most commonly rheumatoid arthritis (33.7%) or psoriasis (15.6%). Median (interquartile range) low-density lipoprotein cholesterol levels were 90.0 mg/dL (79.5-105.5) and 91.5 mg/dL (79.5-108.5) in patients with or without an AIID, respectively (

conclusionsIntensive lowering of low-density lipoprotein cholesterol levels with evolocumab may lead to greater relative reduction in cardiovascular events in patients with an AIID. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01764633.

Indexed as

Anticholesteremic AgentsAtherosclerosisAutoimmune DiseasesCholesterol, LDLInflammationAgedAntibodies, Monoclonal, HumanizedDouble-Blind MethodFemaleHumansMaleMiddle AgedPCSK9 InhibitorsProprotein Convertase 9Treatment OutcomeAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCholesterol, LDLevolocumabPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9autoimmunitycholesterol, LDLinflammationlipidsPCSK9 inhibitors

Identifiers

PMID40255182
PMCPMC12088884

What Socratic holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.